10 May 2016 - Pfizer Canada announced that Health Canada has granted conditional approval of Ibrance (palbociclib) and it is now available in Canada.

Ibrance is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.

For more details, go to: http://www.pfizer.ca/node/7516